MA43258A - Liants pd1/ctla4 - Google Patents

Liants pd1/ctla4

Info

Publication number: MA43258A
Authority: MA; Morocco
Prior art keywords: ctla4; binders
Prior art date: 2015-11-18

Application number

MA043258A

Other languages

English (en)

Inventor

Maribel Beaumont

Carlo Boutton

Edward Bowman

Marie-Ange Buyse

Bruno Dombrecht

Robert A Kastelein

Juha Punnonen

Bjorn Victor

David Vlerick

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-18

Filing date

2016-11-17

Publication date

2018-09-26

2016-11-17 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2018-09-26 Publication of MA43258A publication Critical patent/MA43258A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Developing Agents For Electrophotography (AREA)
Adhesives Or Adhesive Processes (AREA)

MA043258A 2015-11-18 2016-11-17 Liants pd1/ctla4 MA43258A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562256985P	2015-11-18	2015-11-18

Publications (1)

Publication Number	Publication Date
MA43258A true MA43258A (fr)	2018-09-26

Family

ID=57472065

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA043258A MA43258A (fr)	2015-11-18	2016-11-17	Liants pd1/ctla4

Country Status (15)

Country	Link
US (1)	US10544222B2 (fr)
EP (1)	EP3377526A1 (fr)
JP (1)	JP6779997B2 (fr)
KR (1)	KR20180083418A (fr)
CN (1)	CN109071639B (fr)
AR (1)	AR106752A1 (fr)
AU (1)	AU2016355568A1 (fr)
BR (1)	BR112018010085A2 (fr)
CA (1)	CA3003777A1 (fr)
JO (1)	JO3740B1 (fr)
MA (1)	MA43258A (fr)
MX (1)	MX2018006243A (fr)
RU (1)	RU2755724C2 (fr)
TW (1)	TWI782898B (fr)
WO (1)	WO2017087587A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201805064SA (en)	2011-06-23	2018-07-30	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
EP4707303A2 (fr)	2014-05-16	2026-03-11	Ablynx NV	Domaines variables d'immunoglobuline améliorés
IL318433A (en)	2014-05-16	2025-03-01	Ablynx Nv	Improved immunoglobulin variable complexes
MX383464B (es)	2015-07-13	2025-03-14	Cytomx Therapeutics Inc	Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
PE20181326A1 (es)	2015-11-03	2018-08-20	Janssen Biotech Inc	Anticuerpos que se unen especificamente a pd-1 y sus usos
AU2016355569B2 (en)	2015-11-18	2020-01-02	Merck Sharp & Dohme Llc	CTLA4 binders
AU2016357460B2 (en) *	2015-11-18	2023-07-27	Ablynx Nv	Improved serum albumin binders
IL300122A (en)	2015-11-18	2023-03-01	Merck Sharp ַ& Dohme Llc	Substances that bind to PD1 and/or LAG3
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
RU2769282C2 (ru)	2016-06-20	2022-03-30	Кимаб Лимитед	Анти-PD-L1 и IL-2 цитокины
US11858996B2 (en)	2016-08-09	2024-01-02	Kymab Limited	Anti-ICOS antibodies
EP3534947A1 (fr)	2016-11-03	2019-09-11	Kymab Limited	Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
GB201709808D0 (en)	2017-06-20	2017-08-02	Kymab Ltd	Antibodies
GB201721338D0 (en)	2017-12-19	2018-01-31	Kymab Ltd	Anti-icos Antibodies
EP3728314A1 (fr)	2017-12-19	2020-10-28	Kymab Limited	Anticorps bispécifique pour icos et pd-l1
KR20200118423A (ko) *	2018-01-08	2020-10-15	난징 레전드 바이오테크 씨오., 엘티디.	다중특이성 항원 결합 단백질 및 이의 사용 방법
CN111699200B (zh)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	针对pd-1的单域抗体和其变体
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2020057611A1 (fr) *	2018-09-20	2020-03-26	Wuxi Biologics (Shanghai) Co., Ltd.	Nouveaux complexes polypeptidiques ctla-4/pd-1 bispécifiques
CN120623346A (zh) *	2018-10-11	2025-09-12	因荷布瑞克斯生物科学公司	Pd-1单结构域抗体及其治疗组合物
WO2020181402A1 (fr) *	2019-03-10	2020-09-17	胡西木	Polypeptides antitumoraux et utilisation associée
WO2020185722A2 (fr)	2019-03-13	2020-09-17	Merck Sharp & Dohme Corp.	Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
CN111892655B (zh) *	2019-05-06	2022-10-28	四川大学	抗pd-1纳米抗体的筛选及应用
US12565531B2 (en)	2019-12-04	2026-03-03	Jiangsu Alphamab Biopharmaceuticals Co., Ltd.	Bispecific fusion protein for tumor treatment
MX2022007035A (es)	2019-12-09	2022-06-23	Ablynx Nv	Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
AR120698A1 (es)	2019-12-09	2022-03-09	Ablynx Nv	Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
WO2021139776A1 (fr) *	2020-01-10	2021-07-15	Shanghai Henlius Biotech, Inc.	Anticorps anti-tigit, anticorps multispécifiques les comprenant, et leurs procédés d'utilisation
WO2021170750A1 (fr) *	2020-02-28	2021-09-02	Orega Biotech	Polythérapies à base d'inhibiteurs de ctla4 et d'il-17b
CN111944825A (zh) *	2020-08-24	2020-11-17	江苏集萃药康生物科技有限公司	一种ctla4基因和pd1基因人源化小鼠模型的应用
CN114573704B (zh) *	2021-03-10	2022-11-01	北京拓界生物医药科技有限公司	Pd-1/ctla-4结合蛋白及其医药用途
EP4482868A4 (fr) *	2022-02-24	2026-03-04	Merck Sharp & Dohme Llc	Formulations stables d'un lieur d'antigène 4 associé aux lymphocytes t cytotoxiques (ctla4) à base de vhh multivalent se liant au ctla4 humain et leurs procédés d'utilisation
EP4559932A1 (fr) *	2022-07-20	2025-05-28	Minghui Pharmaceutical (Hangzhou) Limited	Anticorps multispécifique et son utilisation
WO2026008665A1 (fr)	2024-07-01	2026-01-08	Vib Vzw	Liants du complexe pd-1•pd-l1 et leur utilisation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0216846B2 (fr)	1985-04-01	1995-04-26	Celltech Limited	Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
EP0663007A1 (fr)	1992-09-29	1995-07-19	The President And Fellows Of Harvard College	Facteur trophique possedant une activite provoquant un canal d'ions dans des cellules neuronales
US6824779B1 (en)	1993-07-26	2004-11-30	Dana-Farber Cancer Institute, Inc.	Methods for inhibiting the interaction of B7-2 with its natural ligand
CA2704600C (fr)	1999-04-09	2016-10-25	Kyowa Kirin Co., Ltd.	Methode de production d'anticorps avec activite adcc accrue
US20020006403A1 (en)	1999-12-14	2002-01-17	Xue-Zhong Yu	CD28-specific antibody compositions for use in methods of immunosuppression
US7795002B2 (en)	2000-06-28	2010-09-14	Glycofi, Inc.	Production of galactosylated glycoproteins in lower eukaryotes
EP2295450B1 (fr)	2000-09-29	2015-01-28	Merck Sharp & Dohme Corp.	Interleukine 10 pegylee
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK1345969T3 (da)	2000-12-26	2010-11-29	Inst Nat Sante Rech Med	Anti-CD28-antistof
CA2466279A1 (fr)	2001-11-13	2003-05-22	Dana-Farber Cancer Institute, Inc.	Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
WO2004041863A2 (fr)	2002-11-08	2004-05-21	Ablynx N.V.	Anticorps a domaine unique diriges contre un interferon gamma et leurs utilisations
ATE485307T1 (de)	2003-11-07	2010-11-15	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (fr)	2004-10-13	2006-04-20	Ablynx N.V.	Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
US8188223B2 (en)	2005-05-18	2012-05-29	Ablynx N.V.	Serum albumin binding proteins
ES2694247T3 (es) *	2005-05-20	2018-12-19	Ablynx N.V.	NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
NZ612578A (en) *	2005-08-19	2014-11-28	Abbvie Inc	Dual variable domain immunoglobin and uses thereof
WO2008020079A1 (fr)	2006-08-18	2008-02-21	Ablynx N.V.	Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
AU2007331672A1 (en) *	2006-12-15	2008-06-19	Ablynx N.V.	Amino acid sequences that modulate the interaction between cells of the immune system
CA2687903C (fr)	2007-05-24	2016-09-13	Ablynx N.V.	Sequences d'acides amines dirigees contre rank-l et polypeptides comprenant ces dernieres, destines au traitement de maladies et affections osseuses
EP2650311A3 (fr)	2007-11-27	2014-06-04	Ablynx N.V.	Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant
EP2285833B1 (fr)	2008-05-16	2014-12-17	Ablynx N.V.	Séquences d'acides aminés dirigées contre cxcr4 et autres gpcr et composés renfermant ces dernières
WO2011006915A2 (fr)	2009-07-16	2011-01-20	Glaxo Group Limited	Domaines variables uniques de liaison anti-albumine sérique améliorés
AU2011275749C1 (en)	2010-07-09	2015-09-17	Aduro Biotech Holdings, Europe B.V.	Agonistic antibody to CD27
EP2723771B1 (fr)	2011-06-23	2019-09-11	Ablynx NV	Protéines se liant à la sérumalbumine
SG10201805064SA (en)	2011-06-23	2018-07-30	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PE20141522A1 (es)	2011-08-17	2014-11-17	Glaxo Group Ltd	Proteinas y peptidos modificados
WO2013066765A1 (fr)	2011-11-01	2013-05-10	Merck Sharp & Dohme Corp.	Mutation de tup1 dans de la levure glycomodifiée
WO2014043509A2 (fr) *	2012-09-13	2014-03-20	Novartis Ag	Molécule de liaison à un antigène à modifications terminales
WO2014111550A1 (fr)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Protéines de liaison modifiées anti-albumine sérique
CN115160441A (zh) *	2013-09-26	2022-10-11	埃博灵克斯股份有限公司	双特异性纳米抗体
GB201322725D0 (en) *	2013-12-20	2014-02-05	Immodulon Therapeutics Ltd	Cancer therapy
EP4707303A2 (fr)	2014-05-16	2026-03-11	Ablynx NV	Domaines variables d'immunoglobuline améliorés
CN104987421A (zh) *	2015-05-13	2015-10-21	北京比洋生物技术有限公司	抗ctla-4和pd-1的双重可变结构域免疫球蛋白

2016
- 2016-11-17 CA CA3003777A patent/CA3003777A1/fr active Pending
- 2016-11-17 JO JOP/2016/0242A patent/JO3740B1/ar active
- 2016-11-17 WO PCT/US2016/062391 patent/WO2017087587A1/fr not_active Ceased
- 2016-11-17 CN CN201680079404.1A patent/CN109071639B/zh not_active Expired - Fee Related
- 2016-11-17 MA MA043258A patent/MA43258A/fr unknown
- 2016-11-17 US US15/353,867 patent/US10544222B2/en active Active
- 2016-11-17 JP JP2018525614A patent/JP6779997B2/ja not_active Expired - Fee Related
- 2016-11-17 EP EP16805653.9A patent/EP3377526A1/fr active Pending
- 2016-11-17 BR BR112018010085A patent/BR112018010085A2/pt not_active IP Right Cessation
- 2016-11-17 AU AU2016355568A patent/AU2016355568A1/en not_active Abandoned
- 2016-11-17 KR KR1020187017234A patent/KR20180083418A/ko not_active Withdrawn
- 2016-11-17 TW TW105137703A patent/TWI782898B/zh not_active IP Right Cessation
- 2016-11-17 MX MX2018006243A patent/MX2018006243A/es unknown
- 2016-11-17 RU RU2018121619A patent/RU2755724C2/ru active
- 2016-11-18 AR ARP160103541A patent/AR106752A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
TW201726739A (zh)	2017-08-01
JP2019502370A (ja)	2019-01-31
EP3377526A1 (fr)	2018-09-26
CN109071639B (zh)	2022-07-08
CA3003777A1 (fr)	2017-05-26
RU2018121619A (ru)	2019-12-18
AU2016355568A1 (en)	2018-06-21
US10544222B2 (en)	2020-01-28
RU2755724C2 (ru)	2021-09-20
US20170137520A1 (en)	2017-05-18
TWI782898B (zh)	2022-11-11
MX2018006243A (es)	2018-11-09
BR112018010085A2 (pt)	2018-11-13
AR106752A1 (es)	2018-02-14
KR20180083418A (ko)	2018-07-20
WO2017087587A1 (fr)	2017-05-26
JO3740B1 (ar)	2021-01-31
JP6779997B2 (ja)	2020-11-04
CN109071639A (zh)	2018-12-21
RU2018121619A3 (fr)	2020-04-24

Publication	Publication Date	Title
MA43258A (fr)	2018-09-26	Liants pd1/ctla4
MA43259A (fr)	2018-09-26	Liants ctla4
DK3411065T3 (da)	2021-07-05	Clec9a-bindingsmidler
DK3283625T3 (da)	2020-03-02	Nukleasemedieret genomeditering
DK3331869T3 (da)	2021-02-15	Muscarinagonister
EP3327220A4 (fr)	2019-02-27	Lieuse
DK3331528T3 (da)	2021-10-25	Muskarinagonister
DK3277719T3 (da)	2022-05-02	Polypeptider
DK3305788T3 (da)	2020-09-28	Janus-kinase-hæmmer
EP3339331A4 (fr)	2019-05-01	Composition
EP3398996A4 (fr)	2019-07-31	Composition
DK3331529T3 (da)	2021-10-18	Muskarinagonister
DK3310450T3 (da)	2019-08-05	Olie-vand-separator
EP3327221A4 (fr)	2019-01-09	Lieuse
EP3345473A4 (fr)	2019-05-22	Moissonneuse-batteuse
DK3270930T3 (da)	2021-10-04	Præeklampsi
EP3351087A4 (fr)	2019-08-21	Moissonneuse-batteuse
EP3395887C0 (fr)	2024-08-28	Composition de caoutchouc fluoré
DK3322295T3 (da)	2022-12-19	Sammensætning
DK3292136T3 (da)	2021-03-22	Penicillin-g-acylaser
DK3274482T3 (da)	2020-01-06	Stenborsknop
DE112015006486A5 (de)	2018-01-04	Inkubationsrinne
EP3396460A4 (fr)	2019-06-26	Racloir
EP3384016A4 (fr)	2019-04-24	Phagémides modifiés
EP3272204A4 (fr)	2019-02-20	Moissonneuse-batteuse